ReviewTrends in molecular medicine2025
Targeting FSH for osteoporosis, obesity, and Alzheimer's disease.
Review in Trends in molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Is Follicle-Stimulating Hormone (FSH) Misnamed? Rethinking Its Role in Menopause as a Systemic Regulator of Bone, Brain, Metabolism, and Aging.Journal of clinical medicine · 2026Review
- From complexity to clarity: aging bone marrow niche in bone and blood regeneration and malignancy.Bone research · 2026Review
- Neuroendocrine and neural control of bone mass in health and disease.The Journal of clinical investigation · 2026Review
- Follicle-Stimulating Hormone in Peripheral Metabolism: Novel Insights into Growth Regulation and Potential Applications in Boar Production.Animals : an open access journal from MDPI · 2026Review
- Article
- Osteoimmuno-brain axis: a bridge connecting osteoporosis and cognitive decline and its clinical significance in dementia and Alzheimer's disease.Frontiers in immunology · 2026Review
- Anthropometric indices and mortality in postmenopausal women: NHANES 1999-2018 evidence.BMC women's health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
Follicle-stimulating hormone (FSH), traditionally known for regulating gonadal development, maturation, and estrogen secretion, has now been implicated in regulating fat and bone metabolism and cognition. Preclinical evidence from genetic and pharmacological studies in rodent models, combined with human data from population-based observations, genetic studies, and a limited number of interventional trials, supports the notion of independent effects of FSH on the skeleton, fat, and brain. This evolving understanding of the nonreproductive roles of FSH presents potential therapeutic opportunities to mitigate age-related health challenges, which include osteoporosis, obesity, cardiovascular risk, and dementia. This review summarizes the current knowledge on the interplay between pituitary-derived FSH and peripheral and central tissues, as well as recent progress in therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.